Patients With Rheumatoid Arthritis (RA) Treated With Rituximab in Kuopio University Hospital

Kuopio University Hospital49 enrolled

Overview

One centre follow-up study on safety and efficacy of treatment with rituximab among patients with RA during 4 year period. Basic data is collected for the national register of biologicals.

Data is collected on regular visits in the outpatient department. In collection national register forms have been used.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Rheumatoid Arthritis

Interventions

rituximabDRUG

rituximab two 1000 mg intravenous infusions separated by two weeks

rituximab, observational study amon patients with active RADRUG

two 1000 mg intravenous infusions separated by 2 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * active RA without response to earlier treatment Exclusion Criteria: * contraindications to rituximab

Locations (1)

Kuopio University Hospital

Kuopio, Finland

Outcomes

Primary Outcomes

ACR20 ACR50 ACR70 response

Time frame: 6 and 12 months

Secondary Outcomes

Duration of clinical response

Time frame: 6 and 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.